MuCaP379AP Cells

Description

MuCaP379AP is derived from the same primary PSA-Cre targeted Pten KO tumor as MuCaP379.1 but exhibits distinct characteristics. Cells are distinguished by their ability to form mixed carcinoma/sarcomatoid carcinoma growth patterns when injected subcutaneously. MuCaP379AP forms syngeneic tumors with a slower growth rate, taking 4-5 months to develop noticeable tumors in immunocompetent mice. This characteristic makes them particularly useful for in vivo studies that require an accurate representation of the histological heterogeneity observed in human prostate cancer. Histologically, MuCaP379AP tumors show a mix of adenocarcinoma and sarcomatoid carcinoma patterns. This cell line has a pronounced immune profile with higher expressions of CD20+ B-cells and CD3+ T-cells compared to faster-growing counterparts. MuCaP379AP is ideal for studying the interplay between tumor growth rates, immune cell infiltration, and the effectiveness of immune-targeted therapies in prostate cancer. The distinct advantage of these cells is their ability to model both epithelial and mesenchymal characteristics of prostate cancer, thus offering a comprehensive tool for cancer research. Additional cell lines from the MuCaP model: Cat. T8301 - MuCaP321 Cells Cat. T8302 - MuCaP376 Cells Cat. T8304 - MuCaP379.1 Cells